[{"NetIncomeLoss_1_Q3_USD":-57963000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":5494000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":15437018.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":15448425.0,"InterestIncomeOther_3_Q3_USD":3897000.0,"InterestIncomeOther_1_Q3_USD":823000.0,"LiabilitiesNoncurrent_0_Q3_USD":548000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":42773000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":421000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":164578000.0,"AssetsCurrent_0_Q3_USD":337601000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":350000.0,"CommonStockSharesIssued_0_Q3_shares":15466451.0,"Assets_0_Q3_USD":339617000.0,"ShareBasedCompensation_3_Q3_USD":15596000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":863000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":15738000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"PreferredStockSharesOutstanding_0_Q3_shares":1969797.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":655622000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3_Q3_USD":205000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1_Q3_USD":-660000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":19136000.0,"CommonStockValue_0_Q3_USD":2000.0,"Revenues_3_Q3_USD":0.0,"Revenues_1_Q3_USD":0.0,"DepreciationDepletionAndAmortization_3_Q3_USD":355000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3_Q3_USD":131380000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q3_USD":53292000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":459000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1_Q3_USD":5061000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-142916000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-58623000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":109120000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":548000.0,"Liabilities_0_Q3_USD":49913000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3_Q3_USD":378088000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"IncreaseDecreaseInAccountsPayableTrade_3_Q3_USD":5099000.0,"OtherIncome_1_Q3_USD":0.0,"RevenueFromContractWithCustomerIncludingAssessedTax_3_Q3_USD":0.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-366341000.0,"CommonStockSharesOutstanding_0_Q3_shares":15466451.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":213186000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-102614000.0,"LiabilitiesCurrent_0_Q3_USD":49365000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3_Q3_USD":62423000.0,"AccountsPayableCurrent_0_Q3_USD":6277000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":109120000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":1664000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":2427000.0,"PreferredStockSharesIssued_0_Q3_shares":1969797.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":1153000.0,"NetIncomeLoss_3_Q3_USD":-143121000.0,"OtherIncome_3_Q3_USD":100000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":513000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":324000.0,"ProfitLoss_3_Q3_USD":-143121000.0,"CommonStockSharesAuthorized_0_Q3_shares":200000000.0,"OperatingIncomeLoss_3_Q3_USD":-147118000.0,"OperatingIncomeLoss_1_Q3_USD":-58786000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":226817000.0,"PreferredStockValue_0_Q3_USD":null,"LiabilitiesAndStockholdersEquity_0_Q3_USD":339617000.0,"PreferredStockSharesAuthorized_0_Q3_shares":5000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":15596000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":5061000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":315000.0,"OperatingExpenses_3_Q3_USD":147118000.0,"OperatingExpenses_1_Q3_USD":58786000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3_Q3_USD":451000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-9.27,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-3.75,"StockholdersEquity_0_Q3_USD":289704000.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":790000.0,"Ticker":"MDGL","CIK":"1157601","name":"MADRIGAL PHARMACEUTICALS, INC.","OfficialName":"Madrigal Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1322434501.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201105"}]